NCT00592163Unknown1 期
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 20
- 主要终点
- toxicities
研究概览
简要总结
A Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with histological or cytological confirmation of advanced cancer that is refractory to standard therapies for their condition.
- •Men and women of ≥18 years of age.
- •ECOG performance score ≤
- •Eligible subjects MUST have at least one measurable lesion as defined by RECIST guidelines. If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology. Measurable lesions MUST NOT have been in a previously irradiated field or injected with biological agents. Eligible subjects with lymphomas must have measurable disease as defined by the revised International Working Group response criteria.
- •Life expectancy ≥12 weeks.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements, to be conducted <2 weeks prior to Baseline:
- •Creatinine ≤1.5 × upper limit of normal (ULN) OR a calculated creatinine clearance ≥50 cc/min
- •Total bilirubin ≤2 × ULN
- •Alanine transaminase (ALT) and aspartate transaminase (AST) ≤3 × ULN
- •Granulocytes in peripheral blood ≥1 × 109/L, hemoglobin ≥10 g/dL, and platelets ≥50,000 /μL
- •Adequate vascular access for repeated blood sampling.
- •Men and women of childbearing potential must agree to use effective contraception from Screening through the duration of Study participation.
- •Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee (IEC/IRB) having jurisdiction over the site.
排除标准
- •New York Heart Association (NYHA) functional class ≥3 myocardial infarction within 6 months
- •Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc ≥450 msec; or a ≥Grade 2 atrioventricular (AV) block or left bundle branch block (LBBB); or documented history of prolonged QTc.
- •Pregnant and/or lactating women.
- •Uncontrolled systemic infection (documented with microbiological studies).
- •Metastatic brain or meningeal tumors.
- •Subjects with seizure disorder requiring medication (such as anti-epileptics).
- •History of confusion or dementia or neurological condition that could mask a potential adverse response to the Study Drug, which may include transient ischemic attack, Parkinson's disease, thrombotic or hemorrhagic stroke, Alzheimers, and other neurological disorders.
- •Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of Study entry (mitomycin C or nitrosureas should not be given within 6 weeks of Study entry).
- •Radiotherapy during study or within 3 weeks of Study entry.
- •Surgery within 4 weeks of start of Study Drug dosing.
- •Investigational drug therapy outside of this trial during or within 4 weeks of Study entry.
- •History of invasive second primary malignancy diagnosed within the previous 3 years except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.
- •Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study or evaluation of Study results.
- •Any condition that is unstable or could jeopardize the safety of the subject and his/her compliance in the Study.
- •Arsenic allergy.
研究组 & 干预措施
Single Arm
Experimental
干预措施: ZIO-101-C (Darinaparsin) (Drug)
结局指标
主要结局
toxicities
时间窗: 6 months
次要结局
- pharmacokinetics(6 months)
研究者
相似试验
已完成
1 期
A Phase I Trial of ZIO-101 in Solid TumorsSolid TumorsNCT00591396Alaunos Therapeutics40
Unknown
1 期
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's LymphomasAdvanced CancerNCT00591422Alaunos Therapeutics23
已完成
1 期
A Phase I Trial of ZIO-101 in Hematologic CancersChronic Myeloproliferative DiseaseChronic Lymphoproliferative DiseasePoor-risk Myelodysplasia (MDS)Multiple MyelomaLymphomaAcute LeukemiaNCT00592046Alaunos Therapeutics12
已完成
1 期
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver DysfunctionAdvanced Solid TumorsHematologic MalignanciesNCT01912222Millennium Pharmaceuticals, Inc.48
已完成
1 期
A Trial of ZL-1201 in Subjects With Advanced CancerAdvanced CancerNCT04257617Zai Lab (Shanghai) Co., Ltd.37